Daniel Guimarães Tiezzi

12PUBLICATIONS
46CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 14, 2026
Neutrophil-lymphocyte ratio as prognostic factor in metastatic breast cancer.

|Dec 30, 2025
The HER2MtGx Metagene Score as a Reliable Tool to Select HER2 Breast Cancer Patients for Neoadjuvant Targeted Therapy.

Daniel Guimarães Tiezzi, Isabela Panzeri Carlotti Buzatto, Willian Abraham da Silveira

|Oct 09, 2024
Potential biomarkers as a predictive factor of response to primary chemotherapy in breast cancer patients.

F O Buono, R D S Pugliese, W A da Silveira

|Aug 23, 2024
Real-world data on adjuvant capecitabine after standard neoadjuvant chemotherapy for triple negative breast cancer.

Maria Fernanda Imperio Pereira, Isabela Panzeri Carlotti Buzatto, Hélio Humberto Angotti Carrara

|Jul 13, 2024
Machine learning can reliably predict malignancy of breast lesions based on clinical and ultrasonographic features.

I P C Buzatto, S A Recife, L Miguel

|Feb 21, 2024
Converging and evolving immuno-genomic routes toward immune escape in breast cancer.

Juan Blanco-Heredia, Carla Anjos Souza, Juan L Trincado

Pageof 2